Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot study to determine whether the drug regadenoson can be used during magnetic resonance imaging to assess regions of poor blood flow to the heart.

The hypothesis of this study is that a single injection of regadenoson could be used instead of a standard adenosine infusion to produce coronary vasodilatation and demonstrate myocardial ischemia during first-pass perfusion cardiac MRI.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Collaborator: Astellas Pharma US, Inc.
• Treatments: Regadenoson

Criteria

Inclusion Criteria:

• reversible perfusion abnormalities on a clinically ordered rest/adenosine dual-isotope SPECT-MPI in at least 2 contiguous myocardial segments (per 17-segment model)

Exclusion Criteria:

• myocardial infarction, myocardial revascularization procedure or progression in angina occuring after the SPECT-MPI examination

• pregnancy

• gadolinium-based MR contrast allergy

• glomerular filtration rate (GFR) > 60 mL/min/1.73 m2

• contraindications to MR imaging (pacemaker, brain aneurysm clips, schrapnel, etc.)